By inhibiting SIRT1 in the presence of either the P53 inhibitor pifithrin‐α or the miR‐34a inhibitor, our other work found that inhibition of P53/miR‐34a improved diabetes‐induced endothelial dysfunction through activation of SIRT1.75 This evidence concerns the gene TP53 and diabetes mellitus.